Medication Adherence in Patients With Sarcoidosis (MAPS)
Medication Adherence and Clinical Outcomes in Sarcoidosis
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Michelle Sharp, MD, MHS
- Phone Number: 410-550-7753
- Email: msharp5@jhmi.edu
Study Contact Backup
- Name: Amanda Sevilla, BA
- Phone Number: 410-550-1859
- Email: Asevill2@jh.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Johns Hopkins Bayview Asthma and Allergy Center
-
Timonium, Maryland, United States, 21093
- Johns Hopkins Greenspring Station
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- At least 18 years of age.
- Physician diagnosis of Sarcoidosis.
- Biopsy proven pulmonary involvement of Sarcoidosis.
- On oral Sarcoidosis medications for at least 6 months.
- Permanently reside in Maryland or D.C.
- Fully vaccinated against COVID-19.
Exclusion Criteria:
- Non-english speaking.
- Unable to provide consent.
- Unable to participate in orally administered questionnaires.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in King's Sarcoidosis Health Questionnaire (KSQ) score
Time Frame: Baseline, 6 months and 12 months
|
The KSQ is a 29-item validated measure of sarcoidosis health status.
Scores range from 0 to 100.
Higher KSQ scores are better.
Lower KSQ scores are worse.
|
Baseline, 6 months and 12 months
|
|
Change in St. George's Respiratory Questionnaire (SGRQ) score
Time Frame: Baseline, 6 months and 12 months
|
The SGRQ is an instrument that contains 50 items in three subscales (symptoms, activity, and impact).
Scores range from 100 to 0. Lower scores for the SGRQ are better and higher scores are worse.
|
Baseline, 6 months and 12 months
|
|
Change in Forced Expiratory Volume (FEV1) as assessed by Pulmonary Function Testing
Time Frame: Baseline, 6 months and 12 months
|
Forced Expiratory Volume (FEV1) will be collected by performing Pulmonary Function Testing using spirometry.
FEV1 is the maximum amount of air that can be forcibly exhaled in one second.
|
Baseline, 6 months and 12 months
|
|
Change in Forced Vital Capacity (FVC) as assessed by Pulmonary Function Testing
Time Frame: Baseline, 6 months and 12 months
|
Forced Vital Capacity (FVC) will be collected by performing Pulmonary Function Testing using spirometry.
FVC is the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.
|
Baseline, 6 months and 12 months
|
|
Change in Diffusing Capacity of Lung for Carbon Monoxide (DLCO) as assessed by Pulmonary Function Testing
Time Frame: Baseline, 6 months and 12 months
|
Diffusing Capacity of Lung for Carbon Monoxide (DLCO) is a measure of the efficiency of lung gas transfer.
DLCO will be collected by performing Pulmonary Function Testing after performing spirometry.
|
Baseline, 6 months and 12 months
|
|
Change in 6-minute walk distance
Time Frame: Baseline, 6 months and 12 months
|
The distance (in meters) a participant is able to walk in 6 minutes will be assessed.
|
Baseline, 6 months and 12 months
|
|
Change in Modified Medical Research Council Dyspnea Scale (MRC) score
Time Frame: Baseline, 6 months and 12 months
|
MRC is a simple scale that has been validated as a method of categorizing patients in terms of their disability attributable to dyspnea.
The scale has 5 items on it.
Scores range from 0 to 4. Higher scores are worse and lower scores are better.
|
Baseline, 6 months and 12 months
|
|
Change in Health Care Utilization (HCU) as assessed by the CRISP Database
Time Frame: 12 months prior to enrollment and the duration of the study for a total of 24 months
|
Health Care Utilization (HCU) for 12 months prior to enrollment and the duration of the study for a total of 24 months will be obtained through the Chesapeake Regional Information System for our Patients (CRISP) database.
With consent, researchers are able to receive real-time notifications whenever a participant receives care at any of the hospitals or long-term care facilities.
Data available on participants includes records from hospitalizations such as discharge summaries, diagnosis, imaging, and laboratory values.
Hospitalization and emergency department (ED) utilization will be coded as a yes/no event.
We will also collect self-report hospitalizations and ED visits from the participants at each study visit.
|
12 months prior to enrollment and the duration of the study for a total of 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Michelle Sharp, MD, MHS, Johns Hopkins University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB00299921
- 1K23HL148527-01A1 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.